spacer
home > epc > summer 2002 > the case for improved clinical logistics - the buck stops here
PUBLICATIONS
European Pharmaceutical Contractor

The Case for Improved Clinical Logistics - The Buck Stops Here

Pharmaceutical procurement officers are concerned at the spiralling cost of research logistics (whatever you perceive that to be). It is estimated that 35 per cent of the fixed and variable costs of a central laboratory pertain to the transport and logistic services they provide. Logistics can account for 50 per cent of study budgets, especially for trials involving infectious diseases with anti-infectives. A recent sponsor survey of central labs which solicited quotes from 13 major laboratories showed a substantial per-visit variance of between US$10 and US$60 in logistic charges only. The central lab industry has long recognised that logistics was the weakest link in the central lab concept. Pharmaceutical companies are beginning to realise this statement could be true for them as well.

Business Environment

To describe the pharmaceutical logistic needs, it is necessary to understand the pharmaceutical research status quo. There are extreme pressures facing all pharmaceutical companies. Globalisation and consolidation has influenced buying and outsourcing behaviour. The term 'strategic partnering' is now a must for any large pharmaceutical company. The secure contractual performance and the 'unloading' of certain liabilities are becoming very attractive.

Scarcity of patients in many therapeutic areas is forcing pharmaceutical companies to more distant geographic locations (outreach) where traditional resources are unavailable, giving rise to a dependency on local contractors. Unlike industries such as automotive or computer technology, the term 'production' for pharma translates to thousands of physicians and co-workers, and this is highly fragmented and expensive to manage. Pharmaceutical companies today use a mix of internal and external vendors to execute a global clinical research programme. It is not only central laboratories that are part of this matrix.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Cocker of MDCPartners

David Cocker is a Biomedical Engineer who began his career in 1977 with Townsend and Mercer London where he was responsible for technology and training in medical imaging. In 1980, David set up his own company in Sydney, Australia, working exclusively with the Australian Red Cross, designing and automating parts for their blood products production. He then moved to Germany and took up the position of Marketing Director for Boehringer Ingelheim's institute Bioscientia, and from this time has held senior positions in a number of leading European clinical laboratories.

He was Founder and General Manager of Medinet in the Netherlands, General Manager for Quintiles European laboratory services and was most recently Managing Director of Clinical Research Laboratory (CRL), based in Brussels. David was a founding member of the European Bio-safety Association. He is also a consultative member on the UN committee of experts on dangerous goods and formal consultant to the WHO on biosafety issues concerning international transport of biological substances.

spacer
David Cocker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement